Genscript Biotech Corp Class H
01548: XHKG (HKG)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
— | — | — | Tvdzrlhm |
GenScript’s Interim Results in Line, Bestzyme Turns Profitable, Revenue Growth Remains Strong
No-moat GenScript’s interim results were in line with our expectations. Revenue from non-cell therapy, or NCT, businesses was USD 248 million for the six months, which represents 27% year-on-year growth. Gross profit margin for the NCT segments declined 4.8 percentage points, which is the continuation of a trend we saw last year. We expect margins to stabilize around current levels. Our fair value estimate is unchanged at HKD 20.50 per share. The market price is a 20% premium to this and we are bullish on the company’s prospects.